Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Dividend Yield Pushes Past 5%
In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $47.55 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
Bristol Myers Squibb: Momentum Still Promising Through H2 2024, Turnaround Likely Prolonged
BMY's rally from the July 2024 bottom is well deserved, as the market rotated from high growth to high dividend-yielding sectors. This is significantly aided by the pharmaceutical company's robust FQ2'24 performance and raised FY2024 guidance. Readers must not forget the numerous tailwinds from H2'24 to 2026 as BMY increasingly monetizes its in-house/acquired pipelines.
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividend payout by 46% over the past five years.
Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and improved guidance support a buy rating, with a valuation target near $76. BMY's technical chart shows bullish signals, including a potential golden cross and improved RSI momentum, indicating a favorable trend.
Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Wells Fargo 2024 Healthcare Conference September 6, 2024 12:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Mohit Bansal - Wells Fargo Cerena Chen - Wells Fargo Mohit Bansal All right. Good morning on a Friday.
Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
BMY has appreciated 26.56% since July but remains undervalued with a 4.8% yield, trading at less than 8 times 2025 earnings. Q2 earnings validated my thesis with a $680 million revenue beat and a $6.47 swing in non-GAAP EPS, showing strong profitability. Rate cuts will allow BMY to refinance nearly $50 billion in debt, reducing interest expenses and boosting margins.
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO
Zenas BioPharma, which is developing immunology-based therapies, said on Friday it is targeting a valuation of as much as $689.7 million in its initial public offering in the United States.
Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.
Bristol-Myers Squibb Company (BMY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody.
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications.
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
An investment in these two stocks could pay off handsomely over the next five to 10 years. Bristol Myers is an established healthcare business with a portfolio of blockbuster drugs.
Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts
Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.
